Reaction
Superior Vena Cava Syndrome reporting signals
As of the last recalculation, Superior Vena Cava Syndrome appears in 598 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is LAPATINIB (PRR 36.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Lapatinib | 16 | 36.9 | 36.9 |
| Pemetrexed | 20 | 33.6 | 33.6 |
| Pemetrexed Disodium | 29 | 27.8 | 27.8 |
| Etoposide | 49 | 25.2 | 25.2 |
| Durvalumab | 13 | 22.7 | 22.7 |
| Erlotinib | 6 | 21.8 | 21.8 |
| Erlotinib Hydrochloride | 7 | 19.7 | 19.7 |
| Brentuximab Vedotin | 5 | 17.1 | 17.1 |
| Carboplatin | 55 | 16.5 | 16.5 |
| Paclitaxel | 43 | 16.2 | 16.2 |
| Gefitinib | 4 | 15.5 | 15.5 |
| Nivolumab | 40 | 15.4 | 15.4 |
| Paclitaxel (Aibumin-Bound) | 34 | 15.2 | 15.2 |
| Polatuzumab Vedotin | 4 | 14.4 | 14.4 |
| Atezolizumab | 15 | 13.8 | 13.8 |
| Gemcitabine | 15 | 13.6 | 13.6 |
| Osimertinib | 11 | 12.1 | 12.2 |